Product
Tuvusertib
Aliases
ATR Kinase Inhibitor M1774, M1774, M 1774, M-1774
8 clinical trials
21 indications
Indication
Endometrial CancerIndication
Endometrial Clear Cell AdenocarcinomaIndication
Endometrial Endometrioid AdenocarcinomaIndication
Ovarian clear cell adenocarcinomaIndication
Endometrioid ovarian adenocarcinomaIndication
Ovarian High Grade Serous AdenocarcinomaIndication
Platinum-Resistant Ovarian CarcinomaIndication
Malignant NeoplasmIndication
Colorectal CancerIndication
Metastatic Malignant Solid NeoplasmIndication
Colorectal Cancer stage IV AJCC v8Indication
Prostate CancerIndication
Advanced Solid TumorIndication
Malignant Solid NeoplasmIndication
Merkel Cell CarcinomaIndication
Stage IV Cutaneous Merkel Cell CarcinomaIndication
Ovarian CancerIndication
Bladder CancerClinical trial
A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial CancerStatus: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774Status: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate CancerStatus: Recruiting, Estimated PCD: 2025-04-25
Clinical trial
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 as a Single Agent and in Combination With the ATR Inhibitor Tuvusertib in Participants With Advanced Solid Tumors (DDRiver 501)Status: Not yet recruiting, Estimated PCD: 2026-03-09
Clinical trial
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination With the ATR Inhibitor M1774Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Randomized Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX TrialStatus: Recruiting, Estimated PCD: 2028-01-01
Clinical trial
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302)Status: Not yet recruiting, Estimated PCD: 2028-01-10
Clinical trial
A Single Arm, Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Avelumab in Combination With the ATR Inhibitor Tuvusertib in Participants With Advanced Urothelial Carcinoma That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)Status: Not yet recruiting, Estimated PCD: 2026-01-12